Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement Record

GenoGenix LLC

Has GenoGenix LLC received an FDA warning letter? Yes. FDA issued a warning letter dated January 20, 2026.

Letter facts

Letter date
January 20, 2026 (2026-01-20)
Issuing office
Center for Drug Evaluation and Research (CDER)
Recipient type
Compounding Pharmacy
Products named
Glutathione MagnesiumReconstitution SolutionEpithalonRapamycinClear Mind 150LIPO (MIC) + BAscorbic Acid Vitamin CAlpha Lipoic AcidImmune Defense Nasal Sprayinjectable methylcobalamin 5,000 mcg/mLinjectable B Complex
Violation categories
Compounding outside 503A/503BCGMP / insanitary conditions

Understanding these violation categories

Compounding outside 503A/503B

FDA says this pharmacy's compounded products did not meet the conditions that let pharmacies compound drugs without FDA approval. A warning letter is FDA's notice of what it believes are significant violations; the company can respond.

CGMP / insanitary conditions

FDA says it observed conditions or manufacturing practices that do not meet current good manufacturing standards, potentially risking product sterility or quality. A warning letter allows the facility to provide corrective actions.

Factual Violation Summary

FDA says sterile drug products compounded with ineligible bulk substances and deficient labeling; produced under insanitary conditions without media fills, environmental monitoring, or airflow validation; CGMP failures; released products with strength below label claim.

Active Drug Ingredients

Statutory Citations & Specific Allegations

  • Failure to meet section 503B conditions (ineligible bulk drug substances, labeling, registration/reporting, adverse event reporting)
  • Adulteration due to insanitary conditions (FDCA 501(a)(2)(A))
  • CGMP violations (FDCA 501(a)(2)(B))
  • Adulteration due to strength failing label claim (FDCA 501(c))

More letters about Semaglutide

Recent FDA warning letters concerning Semaglutide:

Similar violations (Compounding outside 503A/503B)

Recent warning letters with related regulatory findings:

Regulatory Compliance & Editorial Standard:

The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.

Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.